Biopsy for Acute Myeloid Leukemia
This trial is comparing two different ways of treating older patients with a specific type of leukemia. The first treatment method uses a drug to target IDH1 or IDH2 mutations, followed by a combination of azacitidine and venetoclax. The second treatment method uses azacitidine and venetoclax first, followed by the IDH1 or IDH2 inhibitor. Researchers will compare how well each treatment method works and what side effects occur.
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2015 Phase 2 trial • 59 Patients • NCT02150213
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has Biopsy received the green light from the FDA?
"While there is evidence of Biopsy's safety, efficacy data has yet to be collected. This leads our team at Power to give the medication a score of 2 on a scale from 1-3."
Is this clinical investigation still welcoming participants?
"According to clinicaltrials.gov, this medical study has concluded its recruitment process as of June 30th 2022. Initial posting was on August 1st 2022. However, there are currently 1534 other trials actively seeking participants at the moment."